文献速递乳腺癌放疗

早期乳腺癌超低分次全乳放疗联合新型追加照射方案的机构经验

Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer.
PubMed 文献 · Pract Radiat Oncol · 2025-09-22

本研究回顾性分析311例接受26 Gy/5次全乳放疗的早期乳腺癌患者,比较1次5.2 Gy、2次10.4 Gy追加照射与无追加的结局。中位随访32个月,36个月总生存率96%、局部无复发存活率93%,2次追加组急性和晚期毒性发生率更高,单次追加方案安全有效。

要点

  • 26 Gy/5次全乳放疗联合单次5.2 Gy追加或省略追加,疾病控制良好且毒性可接受。
  • 2次10.4 Gy追加组急性和晚期毒性发生率高于单次追加和无追加组。
  • 追加照射、较大追加体积、15×能量、较高乳腺V95%和bolus使用与急性≥2级毒性风险相关。

核心结论

  • 早期乳腺癌采用5次超低分次全乳放疗,省略追加或联合单次5.2 Gy追加,可获得良好疾病控制和可接受的毒性。
  • 2次10.4 Gy追加方案毒性增加,本机构已不再使用。

研究设计与样本

  • 回顾性机构数据库研究,纳入2019年1月7日至2022年1月6日接受辅助全乳放疗26 Gy/5次的非转移性浸润性乳腺癌或导管原位癌患者311例。
  • 追加方案由主治医师决定:54%接受1次追加,8.7%接受2次追加,38%未追加。
  • 采用Kaplan-Meier法估计生存结局,logistic回归评估毒性相关因素。

主要发现

  • 中位随访32个月,36个月总生存率为96%(95%CI 94-99),局部无复发生存率为93%(95%CI 90-97)。
  • 急性毒性发生率:2次追加组37.4%,1次追加组10.8%,无追加组12.2%。
  • 晚期毒性发生率:2次追加组22.7%,1次追加组8.6%,无追加组7.9%。
  • 追加照射、较大追加体积、15×能量、较高乳腺V95%和bolus使用与急性≥2级毒性风险相关。

关键数值与推荐

  • 全乳放疗剂量分割:26 Gy分5次。
  • 追加照射方案:5.2 Gy分1次或10.4 Gy分2次。
  • 36个月总生存率96%(95%CI 94-99),局部无复发生存率93%(95%CI 90-97)。

临床怎么用

  • 对早期乳腺癌患者可考虑26 Gy/5次全乳放疗联合单次5.2 Gy追加或省略追加。
  • 避免使用10.4 Gy分2次追加方案,因毒性增加。
  • 关注追加体积、能量、乳腺V95%和bolus使用等与急性毒性相关的因素。

局限性

  • 回顾性研究设计,追加方案非随机分配,可能存在选择偏倚。
  • 中位随访32个月,长期结局需进一步随访。
  • 单中心机构经验,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 5-year results of the FAST-Forward trial demonstrated noninferiority of local tumor control using a 26 Gy in 5 fraction regimen compared with 40 Gy in 15 fractions for breast cancer patients receiving adjuvant whole breast radiation therapy (WBRT) with or without a sequential conventionally fractionated tumor bed boost (2 Gy per fraction). Here, we reported our institutional experience using the FAST-Forward regimen with a novel sequential boost regimen of 5.2 Gy in 1 fraction or 10.4 Gy in 2 fractions. METHODS AND MATERIALS: Patients with nonmetastatic invasive breast cancer or ductal carcinoma in situ treated with adjuvant WBRT of 26 Gy in 5 fractions from January 7, 2019, to January 6, 2022, were identified from an institutional database. Clinical outcomes, including adverse events, disease control, and patient-reported outcomes, were collected. Survival outcomes were estimated using the Kaplan-Meier method. Associations between toxicities and clinicopathologic and treatment characteristics were assessed using logistic regression. RESULTS: A total of 311 consecutive patients were included; the use of a 1- or 2-fraction boost was left to the discretion of the treating physicians (54% 1-fraction, 8.7% 2-fraction, and 38% no boost). Median follow-up was 32 months. Overall survival and local recurrence-free survival probabilities at 36 months were 96% (95% CI, 94-99) and 93% (95% CI, 90-97), respectively. Acute and late toxicities occurred at a higher rate in the 2-fraction versus 1-fraction and no boost groups (37.4%, 10.8%, and 12.2% [acute] and 22.7%, 8.6%, and 7.9% [late], respectively). Boost receipt, greater boost volume, 15× energy, increasing breast V95%, and bolus use were associated with the risk of acute grade ≥ 2 toxicities. CONCLUSION: A 5-fraction ultrahypofractionated WBRT regimen for early-stage breast cancer with either no boost or a single-fraction boost of 5.2 Gy resulted in excellent disease control and acceptable toxicity. Increased toxicity was observed with a boost of 10.4 Gy in 2 fractions and is no longer used at our institution.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chakraborty MA, Khan AJ, Tadros AB, et al. Ultrahypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer. Pract Radiat Oncol. 2025. PMID: 40992655. doi:10.1016/j.prro.2025.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。